INOVIO PHARMACEUTICALS, INC. — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 27/100
What the filing says
Inovio Pharmaceuticals sold 21,052,632 shares at $0.948 per share plus warrants to purchase 42,105,264 shares at $1.10 per warrant exercise price ($0.95 combined unit price), raising gross proceeds of ~$20 million. Piper Sandler led the underwriting (dated July 29, 2026; closing July 31, 2026). A 90-day lock-up applies to company officers/directors, and underwriters have a 30-day option to purchase additional shares/warrants (3.15M shares, 6.3M warrants) at the same price.
Why this rating
Modest capital raise (~$20M) equals ~27% of Inovio's ~$74M market cap—material for cash but typical biotech financing. Warrant overhang (84M shares potentially issuable, 2:1 warrant ratio) dilutive. Standard underwritten offering terms.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.